AE 101
Alternative Names: AE-101Latest Information Update: 05 Dec 2022
At a glance
- Originator ActualEyes; D. Western Therapeutics Institute
- Developer ActualEyes
- Class Cell therapies; Eye disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fuchs' endothelial dystrophy
Most Recent Events
- 05 Dec 2022 ActualEyes and D. Western Therapeutics Institute plan to proceed with clinical trials in Japan, and file for manufacturing and marketing authorization
- 01 Dec 2022 ActualEyes enter into a joint development agreement with D. Western Therapeutics Institute for the development of AE 101
- 14 May 2021 AE 101 licensed to Arctic Vision in China, Hong Kong, Macau and Taiwan and South Korea